Iatrogenic Cushing's syndrome by an interaction between cobicistat and fluticasone: a case report
SUMMARY We report a case of iatrogenic Cushing's syndrome associated with an interaction between cobicistat and fluticasone in a seropositive woman treated with elvitegravir/cobicistat/emtricitabina/TAF (Genvoya®). This case highlights the importance to review interactions between antirretroviral therapy and other drugs, especially when antirretroviral scheme includes protease inhibitors enhanced with ritonavir or cobicistat. These enhancers interfere the cytochrome P-450 metabolic pathway. A large number of drugs are metabolized by cytochrome P-450 and may be altered by cobicistat or ritonavir.
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Organización de Farmacéuticos Ibero-Latinoamericanos
2021
|
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2021000200204 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | SUMMARY We report a case of iatrogenic Cushing's syndrome associated with an interaction between cobicistat and fluticasone in a seropositive woman treated with elvitegravir/cobicistat/emtricitabina/TAF (Genvoya®). This case highlights the importance to review interactions between antirretroviral therapy and other drugs, especially when antirretroviral scheme includes protease inhibitors enhanced with ritonavir or cobicistat. These enhancers interfere the cytochrome P-450 metabolic pathway. A large number of drugs are metabolized by cytochrome P-450 and may be altered by cobicistat or ritonavir. |
|---|